Literature DB >> 26535533

Bradyarrhythmias Associated with Sofosbuvir Treatment.

Hélène Fontaine, Arnaud Lazarus, Stanislas Pol, Caroline Pecriaux, François Bagate, Philippe Sultanik, Estelle Boueyre, Marion Corouge, Vincent Mallet, Anaïs Vallet-Pichard, Philippe Sogni, Denis Duboc.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26535533     DOI： 10.1056/NEJMc1505967

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  24 in total

Review 1.  Treatment Options in Hepatitis C.

Authors:  Stefan Zeuzem
Journal:  Dtsch Arztebl Int       Date:  2017-01-09       Impact factor: 5.594

Review 2.  Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Authors:  Austin Chan; Keyur Patel; Susanna Naggie
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

3.  Bradyarrhythmia induced by amiodarone-sofosbuvir co-administration.

Authors:  Mohammed El Amine Ghembaza; Ali Lounici
Journal:  Indian J Gastroenterol       Date:  2016-07

Review 4.  Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis.

Authors:  Daniel Caldeira; Filipe B Rodrigues; Marta M Duarte; Carmelo Sterrantino; Márcio Barra; Nilza Gonçalves; Fausto J Pinto; Joaquim J Ferreira; João Costa
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

5.  Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.

Authors:  Jordan J Feld; Marcelo Cypel; Deepali Kumar; Harel Dahari; Rafaela Vanin Pinto Ribeiro; Nikki Marks; Nellie Kamkar; Ilona Bahinskaya; Fernanda Q Onofrio; Mohamed A Zahoor; Orlando Cerrochi; Kathryn Tinckam; S Joseph Kim; Jeffrey Schiff; Trevor W Reichman; Michael McDonald; Carolina Alba; Thomas K Waddell; Gonzalo Sapisochin; Markus Selzner; Shaf Keshavjee; Harry L A Janssen; Bettina E Hansen; Lianne G Singer; Atul Humar
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05-06

6.  The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.

Authors:  Elise J Smolders; Floor Ac Berden; Clara Tmm de Kanter; Wietske Kievit; Joost Ph Drenth; David M Burger
Journal:  United European Gastroenterol J       Date:  2016-11-04       Impact factor: 4.623

Review 7.  Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.

Authors:  Elana S Rosenthal; Shyam Kottilil; Michael A Polis
Journal:  Expert Opin Pharmacother       Date:  2016-03-16       Impact factor: 3.889

8.  Is HIV still a special population for the treatment of hepatitis C?

Authors:  Edward Cachay; Vicente Soriano
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

Review 9.  [Chronic hepatitis C : Standard treatment and remaining challenges].

Authors:  S Zeuzem
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

10.  Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.

Authors:  Seema Mengshetti; Longhu Zhou; Ozkan Sari; Coralie De Schutter; Hongwang Zhang; Jong Hyun Cho; Sijia Tao; Leda C Bassit; Kiran Verma; Robert A Domaoal; Maryam Ehteshami; Yong Jiang; Reuben Ovadia; Mahesh Kasthuri; Olivia Ollinger Russell; Tamara McBrayer; Tony Whitaker; Judy Pattassery; Maria Luz Pascual; Lothar Uher; Biing Y Lin; Sam Lee; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  J Med Chem       Date:  2019-02-07       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.